Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center ...
Tags: Trevena, GPCR biased ligands, BLAST-AHF, acute heart failure